Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 3
1976 2
1977 3
1978 7
1979 6
1980 7
1981 7
1982 13
1983 14
1984 5
1985 9
1986 19
1987 17
1988 19
1989 42
1990 52
1991 43
1992 39
1993 50
1994 54
1995 59
1996 71
1997 48
1998 46
1999 36
2000 42
2001 31
2002 35
2003 29
2004 28
2005 27
2006 31
2007 38
2008 31
2009 33
2010 42
2011 34
2012 28
2013 36
2014 28
2015 27
2016 22
2017 15
2018 22
2019 17
2020 22
2021 23
2022 22
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

1,259 results

Results by year

Filters applied: . Clear all
Page 1
Conventional Chemotherapy Nephrotoxicity.
Gupta S, Portales-Castillo I, Daher A, Kitchlu A. Gupta S, et al. Adv Chronic Kidney Dis. 2021 Sep;28(5):402-414.e1. doi: 10.1053/j.ackd.2021.08.001. Adv Chronic Kidney Dis. 2021. PMID: 35190107 Review.
Ifosfamide and mesna.
Schoenike SE, Dana WJ. Schoenike SE, et al. Clin Pharm. 1990 Mar;9(3):179-91. Clin Pharm. 1990. PMID: 2107997 Review.
Ifosfamide encephalopathy.
Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ajithkumar T, et al. Clin Oncol (R Coll Radiol). 2007 Mar;19(2):108-14. doi: 10.1016/j.clon.2006.11.003. Clin Oncol (R Coll Radiol). 2007. PMID: 17355105 Review.
[Ifosphamide nephrotoxicity].
Ensergueix G, Karras A. Ensergueix G, et al. Nephrol Ther. 2018 Apr;14 Suppl 1:S125-S131. doi: 10.1016/j.nephro.2018.02.008. Nephrol Ther. 2018. PMID: 29606257 French.
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
Bryan LJ, Casulo C, Allen PB, Smith SE, Savas H, Dillehay GL, Karmali R, Pro B, Kane KL, Bazzi LA, Chmiel JS, Palmer BA, Mehta J, Gordon LI, Winter JN. Bryan LJ, et al. JAMA Oncol. 2023 May 1;9(5):683-691. doi: 10.1001/jamaoncol.2022.7975. JAMA Oncol. 2023. PMID: 36928527 Free PMC article. Clinical Trial.
Side effects of ifosfamide.
Klastersky J. Klastersky J. Oncology. 2003;65 Suppl 2:7-10. doi: 10.1159/000073351. Oncology. 2003. PMID: 14586140 Review.
Ifosfamide-induced hyperpigmentation.
Teresi ME, Murry DJ, Cornelius AS. Teresi ME, et al. Cancer. 1993 May 1;71(9):2873-5. doi: 10.1002/1097-0142(19930501)71:9<2873::aid-cncr2820710931>3.0.co;2-6. Cancer. 1993. PMID: 8385568 Review.
Ifosfamide-induced nephrotoxicity in oncological patients.
Quiroz-Aldave JE, Durand-Vásquez MDC, Chávez-Vásquez FS, Rodríguez-Angulo AN, Gonzáles-Saldaña SE, Alcalde-Loyola CC, Coronado-Arroyo JC, Zavaleta-Gutiérrez FE, Concepción-Urteaga LA, Haro-Varas JC, Concepción-Zavaleta MJ. Quiroz-Aldave JE, et al. Expert Rev Anticancer Ther. 2024 Jan-Feb;24(1-2):5-14. doi: 10.1080/14737140.2023.2290196. Epub 2024 Feb 12. Expert Rev Anticancer Ther. 2024. PMID: 38031874 Review.
1,259 results